StockTipsArenaBeta

BUY Piramal Pharma Limited — IDBI Capital

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))20 Aug 2026via IDBI Capital Research Calls Telegram

Entry₹213Stated
Target₹223
Total upside +4.69% (call closed)
Stop loss₹208-2.35% risk
Exit₹20825 Aug 2026, 9:35 am
Stop-loss hit-2.35%
Follow IDBI Capital for new calls(25% target hit, 371 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 147 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 25 Aug 2026
4 supporting1 neutral1 opposing
Supports the BUY call (4)

Piramal Pharma Limited has acquired an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increasing its shareholding from 33.33% to 74.00%. Yapan has now become a subs

NSE · Acquisition·18 Aug · 6d ago

(opens in new tab)

Piramal Pharma Ltd has acquired an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increasing its shareholding from 33.33% to 74.00%. Yapan will now become a subsidi

BSE · Company Update·18 Aug · 6d ago

(opens in new tab)

Piramal Pharma Ltd has provided an update regarding the exercise of a call option to acquire an additional equity stake in Yapan Bio Private Limited.

BSE · Company Update·10 Aug · 2w ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·6 Aug · 3w ago

Neutral / worth noting (1)

Piramal Pharma Block Deal: Seller likely to offload 6% stake for around ₹1,750 crore

NewsCnbc-Tv18·13 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

Piramal Pharma block deal likely cancelled; stock falls 3%

NewsCnbc-Tv18·14 Aug · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from IDBI Capital

Every call and its outcome